Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation may improve outcomes in noncritically ill patients who are hospitalized with Covid-19.
04/07/2021
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Anterior
Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality
Próxima
ABIFINA é nomeada como instituição participante do Grupo Interministerial de Propriedade Intelectual
